New triple drug treatment shows promise against hair loss

A new topical treatment combining three existing medications may offer improved results for people struggling with pattern hair loss, according to recent research.

Hair loss, medically known as Androgenetic Alopecia, affects a large proportion of adults. Estimates from NYU Langone Health suggest that more than 80 per cent of men and nearly half of women experience some form of hair thinning during their lifetime.

Currently, the two main treatments approved by the U.S. Food and Drug Administration are Minoxidil and Finasteride, though both have shown mixed results in clinical use.

Three-drug combination tested

Researchers have developed a new topical therapy called TH07 that combines minoxidil and finasteride with Latanoprost, a drug typically used to treat glaucoma but also known to stimulate eyelash growth.

Minoxidil helps push hair follicles into the active growth phase, while finasteride reduces levels of dihydrotestosterone (DHT), a hormone linked to hair follicle shrinkage and hair loss. Latanoprost is believed to support hair growth by improving follicle activity.

Trial results show encouraging signs

In a clinical study, men with mild to moderate androgenetic alopecia used the treatment once daily for six months.

Researchers found that more than half of the participants using the TH07 combination experienced dense hair regrowth, while others reported moderate improvement.

Participants receiving individual treatments with minoxidil, finasteride or latanoprost showed far less improvement in comparison.

Further studies still needed

Researchers noted that the study had limitations, including a relatively small sample size and a treatment period of only six months.

They said larger and longer-term studies will be needed to confirm whether the combined therapy consistently performs better than existing hair loss treatments.